Issue 39, 2013

A multimodal, β-amyloid-targeted contrast agent

Abstract

A multimodal, β-amyloid-targeted contrast agent was synthesized and studied in vitro. The agent has a higher relaxivity than a clinically approved contrast agent and interacts with β-amyloid aggregates producing changes in relaxation rate and fluorescence emission.

Graphical abstract: A multimodal, β-amyloid-targeted contrast agent

Supplementary files

Article information

Article type
Communication
Submitted
11 Way 2012
Accepted
18 Dit 2012
First published
09 Xim 2012

Chem. Commun., 2013,49, 4148-4150

A multimodal, β-amyloid-targeted contrast agent

S. M. Vithanarachchi and M. J. Allen, Chem. Commun., 2013, 49, 4148 DOI: 10.1039/C2CC36583A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements